Open Access
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +15 more
Reads0
Chats0
TLDR
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.About:
The article was published on 2017-04-01 and is currently open access. It has received 169 citations till now. The article focuses on the topics: Alzheimer's Disease Neuroimaging Initiative & Biomarker (medicine).read more
Citations
More filters
Journal ArticleDOI
Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks
Silvia Basaia,Federica Agosta,Luca Wagner,Elisa Canu,Giuseppe Magnani,Roberto Santangelo,Massimo Filippi +6 more
TL;DR: A deep learning algorithm is built and validated predicting the individual diagnosis of Alzheimer's disease and mild cognitive impairment who will convert to AD (c-MCI) based on a single cross-sectional brain structural MRI scan, demonstrating that it is exploitable by not-trained operators and likely to be generalizable to unseen patient data.
Journal ArticleDOI
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +14 more
TL;DR: Select topics that provide insights into AD progression are discussed and how this knowledge may improve clinical trials are outlined.
Journal ArticleDOI
Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
TL;DR: This paper proposes a novel deep-learning-based framework to discriminate individuals with AD utilizing a multimodal and multiscale deep neural network and delivers 82.4% accuracy and 94.23% sensitivity in classifying individuals with clinical diagnosis of probable AD.
Journal ArticleDOI
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.
Kwangsik Nho,Alexandra Kueider-Paisley,Siamak MahmoudianDehkordi,Matthias Arnold,Shannon L. Risacher,Gregory Louie,Colette Blach,Rebecca Baillie,Xianlin Han,Gabi Kastenmüller,Wei Jia,Guoxiang Xie,Shahzad Ahmad,Thomas Hankemeier,Cornelia M. van Duijn,John Q. Trojanowski,Leslie M. Shaw,Michael W. Weiner,P. Murali Doraiswamy,Andrew J. Saykin,Rima Kaddurah-Daouk +20 more
TL;DR: In this paper, the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF), atrophy (magnetic resonance imaging), and brain glucose metabolism (FDG PET).
Journal ArticleDOI
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
Marc Suárez-Calvet,Marc Suárez-Calvet,Estrella Morenas-Rodríguez,Estrella Morenas-Rodríguez,Gernot Kleinberger,Kai Schlepckow,Miguel Ángel Araque Caballero,Nicolai Franzmeier,Anja Capell,Katrin Fellerer,Brigitte Nuscher,Erden Eren,Erden Eren,Johannes Levin,Johannes Levin,Yuetiva Deming,Laura Piccio,Celeste M. Karch,Carlos Cruchaga,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Michael Ewers,Christian Haass,Christian Haass +24 more
TL;DR: CSF sTREM2 increased in early symptomatic stages of late-onset AD but, unexpectedly, was observed decreased at the earliest asymptomatic phase when only abnormal Aβ pathology but no tau pathology or neurodegeneration, is present.
References
More filters
Journal ArticleDOI
A FDG-PET Study of Metabolic Networks in Apolipoprotein E ε4 Allele Carriers.
Zhijun Yao,Bin Hu,Jiaxiang Zheng,Weihao Zheng,Xuejiao Chen,Xiang Gao,Yuanwei Xie,Lei Fang,Alzheimer’s Disease Neuroimaging Initiative +8 more
TL;DR: The organization of metabolic network in APOE ε4 carriers indicated a less optimal pattern and APOEε4 might be a risk factor for AD.
Journal ArticleDOI
Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
TL;DR: EF/PS decline and right parietal atrophy might act as non-invasive screening tests for abnormal amyloid deposition in cognitively normal elderly and APOE modulation on subsequent trajectories in cognition and atrophy should be taken into account when analyzing disease progression.
Journal ArticleDOI
A kernel machine method for detecting effects of interaction between multidimensional variable sets: An imaging genetics application
Tian Ge,Thomas E. Nichols,Debashis Ghosh,Elizabeth C. Mormino,Jordan W. Smoller,Mert R. Sabuncu +5 more
TL;DR: The method identified that two genes,CR1 and EPHA1, demonstrate significant interactions with CVD risk factors on hippocampal volume, suggesting that CR1 andEPHA1 may play a role in influencing AD-related neurodegeneration in the presence of CVD risks.
Journal ArticleDOI
Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease
Rui Li,Robert Perneczky,Igor Yakushev,Stefan Förster,Alexander Kurz,Alexander Drzezga,Stefan Kramer,Alzheimer’s Disease Neuroimaging Initiative +7 more
TL;DR: A semi-data-driven approach that is based on learning the characteristics of the given data, given some prior anatomical knowledge is introduced, and a Gaussian Mixture Model (GMM) and model selection are combined to return a clustering of voxels that may serve for the definition of ROIs.
Journal ArticleDOI
Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease
TL;DR: The objective of this study was to assess cerebrospinal fluid β‐site amyloid precursor protein (APP)‐cleaving enzyme 1 (BACE1) activity in relation to Alzheimer's disease and to correlate the enzyme activity with protein markers of APP metabolism and axonal degeneration.
Related Papers (5)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Jesse M. Cedarbaum,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Johan Luthman,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Li Shen,Adam J. Schwarz,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +19 more
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Charles DeCarli,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Susan M. Landau,John C. Morris,Ozioma C. Okonkwo,Richard J. Perrin,Ronald C. Petersen,Monica Rivera-Mindt,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,Duygu Tosun,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +20 more